Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Exicure completes Phase 2 trial of GPC-100 for stem cell mobilization in multiple myeloma patients Exicure (NASDAQ: XCUR) completes final patient visit in Phase 2 GPC-100 trial for stem cell mobilization in multiple myeloma; topline results expected Q4 2025. bySoujanya RaviAugust 3, 2025